share_log

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Benzinga Real-time News ·  Nov 16, 2022 08:11

Gainers

  • ANI Pharmaceuticals (NASDAQ:ANIP) shares rose 31.1% to $47.99 during Wednesday's pre-market session. The market value of their outstanding shares is at $837.6 million.
  • Sunshine Biopharma (NASDAQ:SBFM) stock increased by 19.48% to $1.0. The company's market cap stands at $22.5 million.
  • Spruce Biosciences (NASDAQ:SPRB) stock increased by 17.14% to $1.23. The company's market cap stands at $28.9 million. As per the news, the Q3 earnings report came out 4 days ago.
  • Statera BioPharma (NASDAQ:STAB) stock increased by 16.86% to $0.14. The company's market cap stands at $7.4 million.
  • Burning Rock Biotech (NASDAQ:BNR) shares increased by 10.52% to $2.52. The market value of their outstanding shares is at $266.4 million. As per the news, the Q3 earnings report came out yesterday.
  • AirSculpt Technologies (NASDAQ:AIRS) stock moved upwards by 9.71% to $3.39. The market value of their outstanding shares is at $190.4 million. The company's, Q3 earnings came out 4 days ago.

Losers

  • Aptinyx (NASDAQ:APTX) stock declined by 34.9% to $0.21 during Wednesday's pre-market session. The company's market cap stands at $14.4 million.
  • NeuBase Therapeutics (NASDAQ:NBSE) shares declined by 19.56% to $0.23. The market value of their outstanding shares is at $7.5 million.
  • Trevena (NASDAQ:TRVN) stock fell 16.19% to $2.9. The market value of their outstanding shares is at $20.1 million.
  • Lucira Health (NASDAQ:LHDX) shares fell 12.63% to $0.38. The market value of their outstanding shares is at $15.2 million. As per the press release, Q3 earnings came out 2 days ago.
  • Alzamend Neuro (NASDAQ:ALZN) shares declined by 12.13% to $0.98. The market value of their outstanding shares is at $93.9 million.
  • BrainsWay (NASDAQ:BWAY) shares declined by 10.32% to $2.87. The company's market cap stands at $47.4 million. As per the news, the Q3 earnings report came out today. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment